Phasecraft Joins DARPA’s Quantum Benchmarking Initiative
3.3.2026 16:49:00 CET | Business Wire | Press Release
Phasecraft, the world’s leading quantum algorithms company, today announced it has commenced work on the University of Maryland’s Applied Research Laboratory for Intelligence and Security’s (ARLIS) new contract to support the Defense Advanced Research Projects Agency’s (DARPA) ongoing Quantum Benchmarking Initiative (QBI). QBI’s goal is to assess if it is possible to achieve utility-scale quantum computing by 2033. Phasecraft joins the contract as a technical expert and will leverage its proprietary software and quantum algorithms to develop optimized estimates of resource requirements for quantum applications to inform the U.S. Government (USG) verification and validation efforts.
Evaluating Progress Towards Quantum Utility
While the cutting-edge quantum hardware selected for QBI inches closer to commercial utility, ultra-efficient quantum algorithms like those Phasecraft develops are required to unlock the full potential of any quantum hardware. The company’s hardware-agnostic algorithms, which in some cases are millions of times more efficient than the best previous work, enable the company to provide unique value to ARLIS, DARPA, and the USG.
Specifically, Phasecraft’s work will focus on two application areas: 1) materials and molecular modeling; and 2) hard optimization problems. In both cases, Phasecraft’s algorithms have pushed the boundaries of what was thought possible, and radically shortened the timeline to quantum advantage – the point at which quantum computers will outperform classical methods. This enables the company to produce far more accurate estimates of when quantum will deliver true utility to users across application areas.
“The team at DARPA has long understood the strategic importance of quantum computing and we are thrilled at the opportunity to collaborate on this vital work, working alongside ARLIS,” saidAshley Montanaro, co-founder and CEO of Phasecraft. “For all the emphasis we see on hardware in the field, it is gratifying to have a government partner like DARPA appreciate the importance of quantum algorithms in the race to achieve industrially useful quantum computing. Our quantum algorithms are delivering meaningful results today, and we’re excited to join the impressive QBI team.”
Building on Momentum
A preferred research partner for all the leading hardware companies like Google Quantum AI, IBM, Quantinuum and QuEra, Phasecraft prioritizes making quantum useful in the near term. InOctober, Phasecraft unveiled Mondrian, its first-of-a-kind quantum-enhanced software platform designed to speed up classical optimization algorithms and apply them to hard optimization and constraint satisfaction problems across several industries. Mondrian demonstrates how classical and quantum computing can work together to tackle some of the most complex optimization problems facing industries such as energy, finance, and logistics.
This contract comes on the heels of the company’s recent $34M Series B fundraising announcement. The new funding brings the total raised to over $50M – including grant and contract funding – and will allow the company to double down on its R&D breakthroughs and expand industrial efforts, building real-world solutions for end users.
About Phasecraft
Phasecraft is the UK and U.S-based quantum algorithms company whose mission is to accelerate the practical application of quantum computing by redesigning quantum algorithms for the imperfect quantum computers of today. Phasecraft was founded in 2019 by Toby Cubitt, Ashley Montanaro, and John Morton, expert quantum scientists who have spent decades leading top research teams at UCL and the University of Bristol. Phasecraft works in partnership with leading quantum hardware companies, including Google, IBM, Quantinuum, and QuEra, academic and industry leaders, to develop high-efficiency algorithms to move quantum computing from experimental demonstrations to useful applications. Learn more: www.phasecraft.io
View source version on businesswire.com: https://www.businesswire.com/news/home/20260303517174/en/
Contacts
Meredith Bell
+447451298769
meredith@phasecraft.io
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SBC Medical Announces Pricing of Secondary Public Offering of 3.1 Million Shares of Common Stock20.4.2026 01:07:00 CEST | Press Release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“the Company”), a Management Service Organization operating a wide range of franchise businesses across diverse medical fields, today announced the pricing of the underwritten secondary public offering of 3,100,000 shares of the Company’s common stock by Dr. Yoshiyuki Aikawa (the “Selling Stockholder”) at the public offering price of $3.25 per share. Additionally, the Selling Stockholder has granted the underwriters a 45-day option to purchase up to an additional 465,000 shares of the Company’s common stock. The offering is expected to close on or about April 21, 2026, subject to customary closing conditions. The Company is not selling any shares of its common stock in the offering. The Selling Stockholder will receive all of the proceeds from the offering. Maxim Group LLC is acting as the sole book-running manager and Roth Capital Partners is acting as the co-manager for the offering. The offering is being made pursuant to the Com
Horse Powertrain Reveals X-Range C15 Direct Drive Powertrain for Hybridizing BEV Platforms20.4.2026 01:01:00 CEST | Press Release
Horse Powertrain, a global leader in innovative and low-emission powertrain systems, will unveil a new ‘all-in-one’ powertrain at Beijing Auto Show 2026: the X-Range C15 Direct Drive. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260419640202/en/ Left-facing view of the HORSE X-Range C15 Direct Drive The ultra-compact X-Range C15 Direct Drive integrates a full hybrid powertrain – including a 4-cylinder engine, transmission, power electronics, and an electric motor – into a single compact unit with a shared housing, designed to mount to the rear subframe enabling a double isolated installation for best NVH. The X-Range C15 Direct Drive is designed as an ‘all-in-one’ powertrain to replace the rear electric drive unit of an existing BEV platform. It enables an automaker to use a single shared platform for their BEV, HEV, PHEV, and REEV lineups without any significant changes to vehicle design or production environments. The ne
Horse Powertrain Reveals X-Range C15 Direct Drive Powertrain for Hybridizing BEV Platforms20.4.2026 01:01:00 CEST | Press Release
Horse Powertrain, a global leader in innovative and low-emission powertrain systems, will unveil a new ‘all-in-one’ powertrain at Beijing Auto Show 2026: the X-Range C15 Direct Drive. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260419640202/en/ Left-facing view of the HORSE X-Range C15 Direct Drive The ultra-compact X-Range C15 Direct Drive integrates a full hybrid powertrain – including a 4-cylinder engine, transmission, power electronics, and an electric motor – into a single compact unit with a shared housing, designed to mount to the rear subframe enabling a double isolated installation for best NVH. The X-Range C15 Direct Drive is designed as an ‘all-in-one’ powertrain to replace the rear electric drive unit of an existing BEV platform. It enables an automaker to use a single shared platform for their BEV, HEV, PHEV, and REEV lineups without any significant changes to vehicle design or production environments. The ne
Compass Pathways Commends White House Executive Order to Accelerate Research and Access for Psychedelic Treatments18.4.2026 22:12:00 CEST | Press Release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, welcomes the White House Executive Order on accelerating medical treatments for serious mental illness. “We commend the Administration’s Executive Order on psychedelic treatment which recognizes the profound urgency of the mental health crisis facing millions of Americans and the potential impact FDA-approved psychedelics could have,” said Kabir Nath, CEO at Compass Pathways. “Today’s announcement aligns regulatory urgency with patient need, and we applaud the Administration for taking this important step forward in accelerating access, without compromising rigorous science. Compass is conducting the largest, most robust classic psychedelic studies to date with COMP360 synthetic psilocybin. We have recently reported two positive phase 3 trials in treatment-resistant depression (TRD) with highly statistically significant and clinically meaningful data that
Compass Pathways Commends White House Executive Order to Accelerate Research and Access for Psychedelic Treatments18.4.2026 22:12:00 CEST | Press Release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, welcomes the White House Executive Order on accelerating medical treatments for serious mental illness. “We commend the Administration’s Executive Order on psychedelic treatment which recognizes the profound urgency of the mental health crisis facing millions of Americans and the potential impact FDA-approved psychedelics could have,” said Kabir Nath, CEO at Compass Pathways. “Today’s announcement aligns regulatory urgency with patient need, and we applaud the Administration for taking this important step forward in accelerating access, without compromising rigorous science. Compass is conducting the largest, most robust classic psychedelic studies to date with COMP360 synthetic psilocybin. We have recently reported two positive phase 3 trials in treatment-resistant depression (TRD) with highly statistically significant and clinically meaningful data that
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom